Alumis INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

19 Mar 2026

ALMS

10-K: Alumis Reports Positive Phase 3 Envu Data, Secures $300M ATM Facility

Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envu in plaque psoriasis, while also securing a $300 million at-the-market equity offering facility.

NASDAQ

23 Apr 2025

ALMS

Alumis INC

10-K/A: Alumis Inc. Files Amendment to 2024 Annual Report on Form 10-K/A

Alumis Inc. files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and update certain disclosures.

NASDAQ

19 Mar 2025

ALMS

Alumis INC

10-K: Alumis Inc. Files 10-K, Details Merger with ACELYRIN and Clinical Pipeline

Alumis Inc.'s 2024 10-K filing highlights the proposed merger with ACELYRIN, the clinical development of ESK-001 and A-005, and its financial position.